A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers

Trial Profile

A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Tafenoquine (Primary)
  • Indications Vivax malaria
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2017.
    • 08 Sep 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top